Lung cancer is the leading cause of cancer death in the United States, accounting for more deaths than breast, colon, and prostate cancer combined, according to the American Cancer Society's 2025 Cancer Statistics. For thoracic oncology programs, the administrative infrastructure supporting rapid diagnosis, multidisciplinary review, and precision treatment selection is as critical to outcomes as the clinical expertise of the team. Virtual assistants trained in lung cancer workflows are helping programs reduce the administrative delays that widen the gap between diagnosis and curative-intent or life-extending treatment.
Multidisciplinary Tumor Board Coordination
Weekly thoracic tumor boards require assembling radiology imaging, pathology reports, molecular testing results, pulmonary function data, and staging documentation for every patient being presented—often across multiple hospital systems and reference laboratories. For programs reviewing 20–40 cases per week, the case preparation burden is substantial.
Virtual assistants managing tumor board coordination can:
- Collect and organize case documentation from EHR, radiology PACS, pathology systems, and external laboratory portals before each weekly conference
- Prepare case summary packets in standardized format, reducing physician preparation time from an average of 45 minutes per case to under 10 minutes
- Manage case presentation waitlists, prioritizing by disease stage, treatment urgency, and clinical trial eligibility
- Document tumor board recommendations and distribute action items to the treating oncologist, thoracic surgeon, radiation oncologist, and pulmonologist
- Track action item completion, following up with team members when recommended studies or consultations have not been ordered within defined timeframes
The IASLC 2025 Quality Standards Initiative found that programs with structured tumor board administrative support reduced the interval from biopsy to treatment recommendation by an average of 6.4 days.
Immunotherapy Prior Authorization: A Rapidly Evolving Payer Landscape
PD-L1 inhibitors and combination immunotherapy regimens have transformed NSCLC treatment, but they have simultaneously created one of the most authorization-intensive treatment landscapes in oncology. Pembrolizumab, nivolumab, atezolizumab, and durvalumab each carry distinct payer criteria tied to PD-L1 expression thresholds, line of therapy, histology, and concurrent chemotherapy regimens.
Virtual assistants trained in thoracic oncology authorization can manage the full submission process: pulling PD-L1 immunohistochemistry results, confirming line of therapy documentation, verifying ECOG performance status notation, and submitting to the correct payer pathway for each specific regimen. When denials occur—most commonly due to missing biomarker documentation—VAs trained in thoracic oncology can prepare the appeal packet without physician involvement, escalating only when clinical attestation is required.
A 2024 Journal of Oncology Practice study found that practices using dedicated oncology authorization staff—whether in-house or virtual—reduced immunotherapy treatment initiation delays by 8.2 days compared to practices using general front-office staff for authorization.
Molecular and Biomarker Testing Result Tracking
Current NCCN guidelines for advanced NSCLC recommend testing for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS G12C, and PD-L1 at diagnosis—a panel that may be distributed across three or more laboratories with varying turnaround times. A 2024 analysis in JTO Clinical and Research Reports found that 24% of NSCLC patients in community settings had at least one actionable biomarker result arrive after treatment was already initiated, because no structured tracking system existed to hold treatment pending complete results.
Virtual assistants can own the biomarker tracking workflow:
- Create a result matrix for each new NSCLC patient listing all pending tests and expected turnaround times
- Monitor laboratory portals daily for result availability
- Alert the treating oncologist when results arrive, with a summary of actionability linked to current NCCN guidelines
- Coordinate treatment plan adjustments when late-arriving biomarker results reveal targetable mutations
Clinical Trial Enrollment Screening
Comprehensive cancer centers rely on clinical trial enrollment to advance outcomes research, and thoracic oncology has among the highest trial availability in solid tumor oncology. But matching patients to open trials requires reviewing eligibility criteria across multiple tumor board presentations, comparing them against individual patient characteristics, and flagging candidates before treatment planning is finalized.
Virtual assistants can manage trial screening by maintaining an up-to-date portfolio of open thoracic oncology trials, running eligibility screening against patient profiles at tumor board, generating referral summaries for the principal investigator, and tracking screen failures for protocol improvement reporting.
Thoracic oncology programs ready to build the administrative backbone that matches their clinical capabilities can explore purpose-trained virtual assistant support at Stealth Agents.
Sources
- International Association for the Study of Lung Cancer. 2025 Quality Standards Initiative Report. iaslc.org
- American Cancer Society. Cancer Statistics 2025. cancer.org
- Journal of Oncology Practice. "Authorization Staffing Models and Treatment Initiation Delays in Oncology." 2024.
- JTO Clinical and Research Reports. "Biomarker Result Tracking and Treatment Sequencing in Community NSCLC Care." 2024.